Abstract
The prevalence of diabetes and its complications is increasing worldwide. Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease. Although angiotensin-converting-enzyme inhibitors have been cited as the first line of therapy for the management of microalbuminuria, the rate of remission from microalbuminuria to normoalbuminuria has been lower than the expected. Furthermore, due to the elevated frequency of side effects of the rennin-angiotensin blockers new approaches for the treatment of microalbuminuria are needed. Pentoxifylline, a xanthine derivate drug with hemorheologic properties and primarily indicated for the therapy of disturbances of blood fluidity, is also an antagonist of adenosine 2 receptors and have antiinflammatory and immunomodulatory effects, properties that promote beneficial changes in the blood flow conditions and kidney function. Current evidence shows that the short-term use of pentoxifylline has low side-effects, reduces both proteinuria and microalbuminuria in subjects with diabetes, and is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients. Although this data suggests that pentoxifylline could be useful for preventing the development of end-stage renal disease is necessary to conduct long-term studies to evaluate the role of pentoxifylline in the treatment of diabetic nephropathy and the prevention of chronic renal failure. In this article, we review the clinical evidence that show the efficacy of pentoxifylline in the management of microalbuminuria in diabetic patients.
Keywords: Pentoxifylline, Diabetic nephropathy, Microalbuminuria, Proteinuria
Current Diabetes Reviews
Title: Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Volume: 4 Issue: 1
Author(s): Martha Rodriguez-Moran and Fernando Guerrero-Romero
Affiliation:
Keywords: Pentoxifylline, Diabetic nephropathy, Microalbuminuria, Proteinuria
Abstract: The prevalence of diabetes and its complications is increasing worldwide. Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease. Although angiotensin-converting-enzyme inhibitors have been cited as the first line of therapy for the management of microalbuminuria, the rate of remission from microalbuminuria to normoalbuminuria has been lower than the expected. Furthermore, due to the elevated frequency of side effects of the rennin-angiotensin blockers new approaches for the treatment of microalbuminuria are needed. Pentoxifylline, a xanthine derivate drug with hemorheologic properties and primarily indicated for the therapy of disturbances of blood fluidity, is also an antagonist of adenosine 2 receptors and have antiinflammatory and immunomodulatory effects, properties that promote beneficial changes in the blood flow conditions and kidney function. Current evidence shows that the short-term use of pentoxifylline has low side-effects, reduces both proteinuria and microalbuminuria in subjects with diabetes, and is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients. Although this data suggests that pentoxifylline could be useful for preventing the development of end-stage renal disease is necessary to conduct long-term studies to evaluate the role of pentoxifylline in the treatment of diabetic nephropathy and the prevention of chronic renal failure. In this article, we review the clinical evidence that show the efficacy of pentoxifylline in the management of microalbuminuria in diabetic patients.
Export Options
About this article
Cite this article as:
Rodriguez-Moran Martha and Guerrero-Romero Fernando, Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes, Current Diabetes Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339908783502343
DOI https://dx.doi.org/10.2174/157339908783502343 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reducing the Risk of Type 2 Diabetes - Early Identification of High-Risk Individuals and Treatment with Acarbose
Current Diabetes Reviews Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Improving Antihypertensive Agent Selection to Promote Nephroprotection
Current Hypertension Reviews Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Is Inflammation a Common Retinal-Renal-Nerve Pathogenic Link in Diabetes?
Current Diabetes Reviews The Genetics of Small-Vessel Disease
Current Medicinal Chemistry From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Resistance and Hypertension
Current Hypertension Reviews Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Renal Complications of Fabry Disease
Current Pharmaceutical Design Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Current Diabetes Reviews Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Human Islet Transplantation: Current Status and Future Direction
Micro and Nanosystems